Soursop Leaf Supplement Research: The Trial That Did Not Happen

The Oasis Health Journal · Submitted October 16, 2026 · 10:30 AM EDT

By Marlo Quist · Edited by Priya Raman, C.N.C.

The soursop leaf supplement you can order today has never been tested on a human being in a controlled trial.

Not for blood sugar. Not for safety. Not for anything.

The leaf comes from Annona muricata, a tropical tree also called graviola. Extracts from various parts of the plant contain acetogenins, a class of compounds that interfere with mitochondrial function in laboratory settings. Researchers have studied these molecules in computers, petri dishes and rodents. They have published reviews, filed patents and written about therapeutic potential.

What they have not done is give the soursop leaf supplement to people and measure what happens.

A Computer Had Thoughts

A 2026 computational study screened 123 natural acetogenins from A. muricata against a bacterial protein called LuxS, which helps bacteria coordinate their behaviour through quorum sensing. The researchers used molecular docking software to predict how well each compound would bind to the protein. Two acetogenins, gigantetronenin and isoannonacin, showed promising binding scores in the simulation.

In silico means it happened inside a computer.

Not in a bacterium. In a Dell.

The study did not test the compounds on actual bacteria. It ran the numbers and reported that the fit looked good. The authors wrote that these findings 'highlight the potential' of the acetogenins as therapeutic candidates.

Potential means maybe later. Maybe never. The word does not care.

Molecular docking studies predict interactions. They do not measure them. A compound that docks well in a model may do nothing in a living system, or it may never reach the site, or it may get metabolised first. The study identified candidates. That is all it did.

The Cancer Studies Used Everything But Leaves

Multiple reviews describe Annona muricata extracts in cancer research. A 2022 review in Cancers summarised studies on extracts from the fruit, bark, seeds, roots and leaves, noting that acetogenins downregulate anti-apoptotic genes and interfere with proteins involved in cell invasion and metastasis in various cancer cell lines. The review states that active phytochemicals in A. muricata 'have the potential to be employed as a promising anti-cancer agent.'

A cell line is not a person.

A person is bigger and has a liver and does not live in a petri dish.

A 2018 review in Carcinogenesis examined graviola constituents and noted that dozens of acetogenins are present in different parts of the plant. It described the compounds' effects on mitochondrial glucose oxidation and ATP production in cultured cells and concluded that the plants 'could have both chemopreventive and therapeutic potential.' The review also noted that 'appropriate attention to safety studies will be important.'

Important means it has not happened yet.

The reviews cite in vitro studies and animal models. They do not cite human trials because there are none. A 2026 systematic review of African medicinal plants and triple-negative breast cancer included Annona muricata in its analysis and reported IC50 values as low as 5.10 micrograms per millilitre for Catharanthus roseus and other species, but noted that 'the lack of clinical trials and end-to-end drug development infrastructure on the continent remains a significant barrier.'

The barrier is the part between the petri dish and the pharmacy.

That is the whole middle of drug development and nobody has built it.

The Rat Prostate Study Tested Seeds

A 2026 study in BMC Complementary Medicine and Therapies gave thirty male rats testosterone injections for 28 days to induce benign prostatic hyperplasia, then treated subgroups with 200, 400 or 600 milligrams per kilogram body weight of Annona muricata seed extract daily for 21 days. The researchers measured prostate weight, serum markers and histological changes, and reported that the extract reduced prostate size and oxidative stress markers compared to untreated controls.

The seeds are not the leaves.

Also the rats did not wake up with enlarged prostates. The study gave them testosterone until it happened, then treated the thing it caused. That is a model, not a disease.

The dose used in rats does not translate directly to humans. The duration was three weeks. The study measured prostate tissue changes, not blood glucose or anything else the soursop leaf supplement marketing implies.

The title of this piece says soursop leaf supplement.

The rat study tested seed extract.

Different plant parts. Different acetogenin profiles. The supplement industry does not care about that.

What You Can Buy Versus What Got Measured

You can order soursop leaf capsules, powders and tinctures from multiple suppliers. The labels reference traditional use, antioxidant content and immune support. None of them reference a human clinical trial.

There is not one to reference.

A 2026 review of patent filings noted that Annona muricata appears in applications for antitumoral, anti-inflammatory and antidiabetic uses, as well as cosmetic formulations for anti-aging, anti-acne, hair loss and skin whitening.

A patent filing is not evidence. It is someone hoping to own something later.

The gap between the research and the retail product is every stage of drug development: safety trials, dose-finding studies, pharmacokinetics, bioavailability measurement, interaction screening and efficacy testing in the condition the marketing implies. For soursop leaf supplements, that entire middle section is missing.

The in vitro work is real. The rodent studies are real. The human data is not there.

Acetogenins inhibit mitochondrial complex I, the first enzyme in the electron transport chain. That mechanism works in cancer cells and in healthy cells. Chronic inhibition of complex I is the proposed mechanism behind atypical parkinsonism observed in populations consuming large amounts of soursop fruit and leaf tea in the Caribbean. A 2018 review noted the concern and recommended safety studies.

Those studies have not been published.

The research identified active compounds, demonstrated effects in isolated systems and described potential. It did not establish safe doses, measure outcomes in people or show that the soursop leaf supplement you can buy does what the petri dish studies suggest.

Computational models predict. Animal studies model. Human trials measure.

This subject has the first two.

This article is education and reporting on published research. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Talk to your own clinician about your own situation.

Sources

1. Computer-Aided Identification and Molecular Interaction Analyses of Annona muricata Acetogenins Against LuxS, Biotechnology and applied biochemistry (2026).
2. A Review on Annona muricata and Its Anticancer Activity, Cancers (2022).
3. Molecular Targets of Natural Compounds with Anti-Cancer Properties, International journal of molecular sciences (2021).
4. Emerging therapeutic potential of graviola and its constituents in cancers, Carcinogenesis (2018).
5. Innovation and Biodiversity: Patent Trends in Therapeutic and Cosmetic Use of Scientifically Relevant Pantanal Plants, Plants (Basel, Switzerland) (2026).
6. African Medicinal Plants Targeting Triple-Negative Breast Cancer (TNBC): A Systematic Review of Ethnobotanical Surveys, Phytochemistry and Anti-TNBC Studies, Pharmaceuticals (Basel, Switzerland) (2026).
7. Ameliorative effect of Annona muricata seed extract on testosterone-induced benign prostatic hyperplasia in rats: biochemical, histopathological, and in silico evidence of 5-alpha reductase inhibition, BMC complementary medicine and therapies (2026).